Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced ...

Belite Bio Inc (NASDAQ: BLTE) stock falls after reporting Q3 net loss of $36.1M; analysts maintain Buy/Overweight rating, citing positive trial results.

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal ...

We made exciting progress in our clinical development efforts over the past year, and the recent completion of the interim analysis of the ...

Belite Bio, Inc (NASDAQ:BLTE – Get Free Report) shares gapped down prior to trading on Monday following a weaker than expected earnings announcement. The stock had previously closed at $67.45 ...

Belite Bio, Inc. announced progress in its clinical trials, including a positive recommendation from the Data Safety Monitoring Board for its Phase 3 DRAGON trial in adolescent Stargardt 1 (STGD1 ...

Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio Fourth Quarter and Full Year 2024 Earnings Conference Call. After today’s prepared remarks, we will host question ...

These statements include but are not limited to statements regarding the potential implications of clinical data for patients, interim analysis and recommendation from DSMB; Belite Bio’s ...

Belite Bio Inc ADR (BLTE) held its Q4 2024 earnings call, revealing a consistent financial performance with a reported net loss of $36.1 million for the year, up from $31.6 million in 2023.

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report ...

These statements include but are not limited to statements regarding the potential implications of clinical data for patients, and Belite Bio’s advancement of, and anticipated preclinical ...

Belite Bio Inc ADR (BLTE) held its Q4 2024 earnings call, revealing a consistent financial performance with a reported net loss of $36.1 million for the year, up from $31.6 million in 2023. The ...